Discover and read the best of Twitter Threads about #IMS2022
Most recents (11)
Last day of IMS.
Debate: are we over-treating with hormone therapy?
First speaker Prof Martha Hickey (Australia)
For the motion. #IMS2022
Debate: are we over-treating with hormone therapy?
First speaker Prof Martha Hickey (Australia)
For the motion. #IMS2022
Argues that the only primary indication for MHT is VMS (not mood, not sleep and not for primary prevention of disease).
Quotes US preventive task force.
Quotes US preventive task force.
Discusses Collaborative group on hormonal factors in breast cancer. (Lancet)
Observational study.
#IMS2022
Observational study.
#IMS2022
Final plenary for today.
The microbiome: endocrine nexus in human health.
Prof Jack Gilbert (US). #IMS2022
The microbiome: endocrine nexus in human health.
Prof Jack Gilbert (US). #IMS2022
Our immune system regulates our microbiome.
Can be in a state of homeostasis or dysbiosis.
Dysbiosis can lead to diseases.
Can be in a state of homeostasis or dysbiosis.
Dysbiosis can lead to diseases.
During menopause a reduction in microbiome diversity tends to occur.
Can affect hormones and metabolic factors eg lipids, and weight.
May affect brain chemistry and mood too.#IMS2022
Can affect hormones and metabolic factors eg lipids, and weight.
May affect brain chemistry and mood too.#IMS2022
IMS symposium on CVD at midlife.
First speaker Prof Chrisandra Shufelt (USA).
MHT and CVD: looking back before moving forward.
First speaker Prof Chrisandra Shufelt (USA).
MHT and CVD: looking back before moving forward.
ELITE looked at CIMT in groups <6 or >10 yrs post menopause. Increase in CIMT was lower in the early menopause group but not at a level to affect relative risk for CVD. #IMS2022
IMS Congress day 3.
Starting very early with concurrent presentations from menopause societies.
AMS presentation on Menopause and work.
Chaired by Dr Sylvia Rosevear (Aotearoa/NZ). menopause.org.au
Starting very early with concurrent presentations from menopause societies.
AMS presentation on Menopause and work.
Chaired by Dr Sylvia Rosevear (Aotearoa/NZ). menopause.org.au
I was the first speaker.
Case studies in menopause at work.
I began by acknowledging that some people who experience menopause don’t identify as women. Gender diverse people can also experience menopause.
#IMS2022
Case studies in menopause at work.
I began by acknowledging that some people who experience menopause don’t identify as women. Gender diverse people can also experience menopause.
#IMS2022
Whether a workplace is menopause supportive or not can make the difference between someone staying in their workplace or leaving.
This in turn can have long term impacts including on life trajectory, and retirement income. #IMS2022
This in turn can have long term impacts including on life trajectory, and retirement income. #IMS2022
Next session. Hormones.
First speaker Prof Alfred Mueck.
Principles to select estrogens.
Conjugated equine estrogens - contain a lot of substances, in variable amounts.
Suggests we move away from its use. #IMS2022
First speaker Prof Alfred Mueck.
Principles to select estrogens.
Conjugated equine estrogens - contain a lot of substances, in variable amounts.
Suggests we move away from its use. #IMS2022
Estradiol containing COCPs. Took a while to develop because of bleeding issues.
Now we have pills with good cycle control, because of the progestogen. Dienogest or nomegestrol. #IMS2022
Now we have pills with good cycle control, because of the progestogen. Dienogest or nomegestrol. #IMS2022
Next speaker Prof Nick Panay. (UK)
Optimizing hormone therapy through choice of progestogen/progesterone.
#IMS2022
Optimizing hormone therapy through choice of progestogen/progesterone.
#IMS2022
Next session. Debate. MHT for primary prevention. For: Prof Robert Langer. Begins by revisiting WHI #IMS2022
Describes preventive effects of MHT on CHD and other conditions. Choice of progestogen important. #IMS2022
Against: Prof Mary Ann Lumsden (UK).
I’ll be tweeting when I can from the International Menopause Society Congress.
#IMS2022
#IMS2022
Starting with the meeting before the meeting.
The Council of Affiliated Menopause Societies.
Societies from around the world connecting and collaborating.
Welcome from IMS President Steven Goldstein.
#IMS2022
The Council of Affiliated Menopause Societies.
Societies from around the world connecting and collaborating.
Welcome from IMS President Steven Goldstein.
#IMS2022
New CAMS chair Dr Duru Shah pointing out that the number of women over 60 is expected to double by 2050.
UN priority is to reduce health inequities and ageism and promote healthy aging.
UN priority is to reduce health inequities and ageism and promote healthy aging.
Bispecifics for myeloma are promising. As I said earlier, I’d like them all get accelerated approval.
But as clinicians we must swiftly adjust dosing schedule & be watchful to risk of severe infections & other cancers that can occur with prolonged T cell suppression. #IMS2022
But as clinicians we must swiftly adjust dosing schedule & be watchful to risk of severe infections & other cancers that can occur with prolonged T cell suppression. #IMS2022
Overall survival is a composite endpoint. It not only depends on efficacy but also safety.
At this meeting talking to colleagues, I am increasingly aware of the risk of serious infections with these agents.
At this meeting talking to colleagues, I am increasingly aware of the risk of serious infections with these agents.
As @TomBmt133 pointed out severe infections and deaths due to infections with bispecifics and CART must be considered possibly related to therapy and not classified as unrelated.
Dr. Thierry Facon making a compelling argument for autologous stem cell transplant for newly diagnosed myeloma. @Myeloma_Society #IMS2022
For high risk myeloma, its important to consider early transplant in the frontline setting.
For standard risk myeloma, we continue to prefer early transplant but in certain circumstance can delay transplant until first relapse accommodating patients’ wishes & life circumstances
For standard risk myeloma, we continue to prefer early transplant but in certain circumstance can delay transplant until first relapse accommodating patients’ wishes & life circumstances
Although we have multiple options to treat myeloma, the number of highly effective drug classes are few and just not enough.
We continue to have an unmet need for relapsed myeloma. We continue to need accelerated approval by the FDA. @Rfonsi1 @NorthTxMSG #IMS2022 #IMS2022VR
1/
We continue to have an unmet need for relapsed myeloma. We continue to need accelerated approval by the FDA. @Rfonsi1 @NorthTxMSG #IMS2022 #IMS2022VR
1/
We also need accelerated approval of multiple drugs of the same class because patients tolerate one better than the other, and sometimes one works better than the other. It is also important to have competition to foster more innovation and to have some effect on price.
2/
2/
The fact we have made so much progress in myeloma does not mean we don’t need more drugs.
Myeloma remains a serious malignancy and we continue to have unmet needs. So I will continue to advocate for rapid approval of new drugs.
3/
Myeloma remains a serious malignancy and we continue to have unmet needs. So I will continue to advocate for rapid approval of new drugs.
3/
